Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma ; volume:14 ; number:1 ; day:10 ; month:9 ; year:2024 ; pages:1-11 ; date:12.2024
Scientific reports ; 14, Heft 1 (10.9.2024), 1-11, 12.2024
- Urheber
-
Lee, Kyeongmi
Cha, Honghui
Kim, Jaewon
Jang, Yeongjun
Son, Yelin
Joe, Cheol Yong
Kim, Jaesang
Kim, Jhingook
Lee, Se-Hoon
Lee, Sanghyuk
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-72108-5
- URN
-
urn:nbn:de:101:1-2411242113553.918137317523
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Kyeongmi
- Cha, Honghui
- Kim, Jaewon
- Jang, Yeongjun
- Son, Yelin
- Joe, Cheol Yong
- Kim, Jaesang
- Kim, Jhingook
- Lee, Se-Hoon
- Lee, Sanghyuk
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy : = Kutane, gastrointestinale, hepatische, endokrinologische und renale Nebenwirkungen unter anti-PD-1 Therapie
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone